Pharos iBio파로스아이바이오
388870 · KOSDAQ · ₩388870 · 파로스아이바이오
What brokers say about Pharos iBio
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Pharos iBio remains loss-making with no reported revenue, and its shares have risen sharply over the past year from a 52-week low.
Pharos iBio is a Korean drug developer focused on rare and hard-to-treat cancers, using an AI-based discovery platform and aiming to license its candidates rather than sell finished drugs. The trailing twelve-month figures to H1 2026 show an operating loss of about ₩10.6B... wait
Data as of Oct 27, 2026 · written 9h ago
This is not financial advice.
Also known as: Pharos iBio / 파로스아이바이오 / 388870 / KRX:388870
Source: KRX statistical information